Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy

Inclusion Criteria: * Renal biopsy was performed before randomization and pathologically diagnosed as idiopathic membranous nephropathy; * Anti-phospholipase a2 receptor (PLA2R) antibody is positive; * Aged from 18 to 75, either sex; * Tolerable doses of RASI were received for ≥4 weeks before randomization, nephrotic syndrome was not in remission and 24-hour urinary protein level was ≥3.5g/24h and \< 8.0g/24h; * The eGFR≥45ml/min/1.73m2 (Measured at least twice in 2 weeks); * The patient is willing to sign the informed consent form. Exclusion Criteria: * Diagnosed as secondary membranous nephropathy; * Rapidly progressive membranous nephropathy (eGFR decreased by 50 % compared with the baseline level within 3 months); * Receiving renal replacement therapy; * Diabetes and glycosylated hemoglobin (HbA1c) levels ≥ 7.0%; * Hypertension is not well controlled (systolic blood pressure\>160mmHg or diastolic blood pressure\>100mmHg); * The level of serum albumin≤20g/L; * Resistance to treatment with CsA or other CNI, rituximab (RTX) or alkylating agents; complete remission or partial remission was obtained after treatment with CNI, RTX, or alkylating agents but there was a history of relapse within 3 months； * Suspected infection by imaging and/or laboratory tests; * Infectious diseases, such as hepatitis B, hepatitis C, AIDS, tuberculosis; * History of malignant tumor; * Hepatic dysfunction: aspartate aminotransferase (AST) concentration and alanine aminotransferase (ALT) concentration of \> 1.5 × upper limit of normal; * Allergic to Huaier granule or Ciclosporin soft capsules; * Previous CNI treatment was ineffective; * Complicate with any diseases that may affect efficacy and safety evaluation; * Pregnant or lactating women, and patients (male or female) with fertility plans or unwilling to take effective contraceptive measures; * Participating in other clinical trials or participated in other clinical studies within 3 months; * According to the researchers, patients have diseases or conditions that increase the difficulty of enrollment or probability of loss to follow-up, such as mental illness, frequent changes in residence and work, etc.